Private Wealth Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Private Wealth Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.52K	Hold	218	–	–	﹤0.01%	815
2026 Q1	$4.85K	Hold	218	–	–	﹤0.01%	784
2025 Q4	$5.82K	Hold	218	–	–	﹤0.01%	715
2025 Q3	$4.65K	Hold	218	–	–	﹤0.01%	817
2025 Q2	$4.7K	Sell	218 -72	-25%	-$1.34K	﹤0.01%	777
2025 Q1	$4.82K	Hold	290	–	–	﹤0.01%	741
2024 Q4	$5.32K	Buy	+290	New	+$4.68K	﹤0.01%	717
2024 Q3	–	Sell	-63	Closed	-$1.02K	–	1500
2024 Q2	$1.02K	Buy	63 +20	+47%	+$323	﹤0.01%	1283
2024 Q1	$796	Hold	43	–	–	﹤0.01%	1339
2023 Q4	$1.35K	Buy	+43	New	+$1.03K	﹤0.01%	1155

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Private Wealth Management Group's ACAD Position: Q2 2026 in Review

Private Wealth Management Group held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 218 shares worth $5.52K. The position accounts for ﹤0.01% of the portfolio, ranked #815.

Private Wealth Management Group first reported a position in ACAD in Q4 2023 and has held it in 10 quarters since. The position peaked at $5.82K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Private Wealth Management Group held 218 shares of Acadia Pharmaceuticals worth $5.52K as of Q2 2026.
Private Wealth Management Group left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #815 holding.
Private Wealth Management Group first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Private Wealth Management Group's Acadia Pharmaceuticals position peaked at $5.82K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.